Synthetic Genomics had in June made an initial close at $10m from one investor out of a targeted $50m but has now gathered $35m from six backers.
Synthetic Genomics, a US-based biotechnology company founded by Craig Venter, a pioneer in reading the human genome, has extended its latest round to $35m, according to its regulatory filing.
Synthetic Genomics had in June made an initial close at $10m from one investor out of a targeted $50m.
The latest close has come from six undisclosed investors. Oil major BP bought a stake of undisclosed size in 2007 and joined Synthetic Genomics’ original venture capital backers: Biotechonomy, Draper…
